Biotech stocks plummet as FDA vaccine chief resigns amid conflict with HHS Secretary Kennedy, raising concerns over regulatory uncertainty.
BlackRock CEO Larry Fink shifts focus from ESG to economic growth and infrastructure investment, responding to political pushback against his previous ESG agenda.
Biotech stocks plummet as FDA vaccine chief resigns amid conflict with HHS Secretary Kennedy, raising concerns over regulatory uncertainty.
BlackRock CEO Larry Fink shifts focus from ESG to economic growth and infrastructure investment, responding to political pushback against his previous ESG agenda.